Alfred Sandrock, M.D., Ph.D., and Spyros Artavanis-Tsakonas, Ph.D., will lead Biogen R&D
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Douglas Williams, Ph.D., will leave Biogen (NASDAQ: BIIB) at the end of July to become CEO of as-yet unnamed start-up biotechnology company. Dr. Williams will be the first member of a new organization with potential in cancer diagnostics and therapy.
Language:
English
Contact:
MEDIA CONTACT:
Biogen
Daniel McIntyre, +1 781-464-3260
public.affairs@biogen.com
or
INVESTOR CONTACT:
Biogen
Carlo Tanzi, Ph.D., +1 781-464-2442
IR@biogen.com
Ticker Slug:
Ticker:
BIIB
Exchange:
NASDAQ
ISIN:
US09062X1037
